Physicians' Academy for Cardiovascular Education
Nick Nurmohamed explains what Lp(a) is and how correction of LDL-c for Lp(a) reduces genetic testing for FH.
Among asymptomatic phenotypic FH patients, patients with a genetically confirmed FH diagnosis had a higher frequency and severity of coronary atherosclerotic plaques, compared to those without a FH-causing mutation.
In this video, internist Kees Hovingh discusses why screening for FH is important and how to identify individual FH patients and their families. With question to test your knowledge.
This study showed that incorporation of genetic testing results in increased numbers of patients diagnosed with definite FH, compared to classification based solely on clinical criteria.
Rens Reeskamp discusses tools that may help to increase the chance of finding FH patients. With question to test your knowledge.
This phase 2 study with alirocumab decreased LDL-c levels and was generally well tolerated in pediatric HeFH patients. Two dosing regimens were selected for further investigation in a phase 3 trial.
Statins lowered total cholesterol, LDL-c, triglycerides and apo-B levels and increased HDL-c levels in children and adolescents with FH, as shown in this systematic review and meta-analysis.
Compared to worldwide FH prevalence in the general population, FH prevalence is higher in subpopulations of subjects with IHD and severe hypercholesterolemia, as demonstrated by meta-analyses.
Pediatric cardiologist Bert Wiegman discusses the need for early detection and treatment of children with familial hypercholesterolemia. With question to test your knowledge.
ACC 2020 Dirk Blom discusses the design and outcomes of the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.
ACC 2020 An antibody against angiopoietin-like protein 3 (ANGPTL3) resulted in lowering of LDL-c in homozygous FH patients, independent of LDL receptor function.
ACC 2020 The ODYSSEY HoFH trial demonstrated that treatment with alirocumab reduced LDL-c in HoFH patients compared to placebo, and alirocumab was found to be well tolerated and safe.
